文献速递炎症性肠病食管胃疾病与幽门螺杆菌

长期使用质子泵抑制剂与炎症性肠病风险:三项前瞻性队列的汇总分析

Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts.
PubMed 文献 · Gastroenterology · 2021-08-11

该研究汇总护士健康研究(NHS,n=82,869)、NHS II(n=95,141)和英国生物银行(n=469,397)三项前瞻性队列,评估规律使用质子泵抑制剂(PPI)与炎症性肠病(IBD)及其亚型风险的关系。结果显示,规律使用PPI者IBD风险较非使用者升高(HR 1.42,95%CI 1.22-1.65),与H2受体拮抗剂直接比较亦显示PPI使用与更高IBD风险相关(HR 1.38,95%CI 1.16-1.65)。作者指出绝对风险较低且PPI临床获益显著,应谨慎解读。

要点

  • 规律使用PPI与IBD、克罗恩病及溃疡性结肠炎风险升高相关。
  • 汇总分析显示PPI使用者IBD风险HR为1.42(95%CI 1.22-1.65)。
  • 与H2受体拮抗剂相比,PPI使用仍与更高IBD风险相关(HR 1.38)。

核心结论

  • 规律使用PPI与IBD及其亚型(克罗恩病和溃疡性结肠炎)风险升高相关。
  • 作者强调绝对风险较低且PPI临床获益显著,研究结果应谨慎解读。

研究设计与样本

  • 汇总分析护士健康研究(NHS,n=82,869)、NHS II(n=95,141)和英国生物银行(n=469,397)三项前瞻性队列。
  • 纳入基线时无IBD或癌症且有个人PPI使用信息的参与者。
  • 采用Cox回归评估风险比(HR)及95%置信区间(CI),校正生活方式因素、PPI适应证、合并症及其他药物。

主要发现

  • 汇总NHS队列中位随访12年记录271例IBD,英国生物银行中位随访8.1年记录1419例IBD。
  • 汇总NHS队列与英国生物银行均显示规律使用PPI与IBD、克罗恩病和溃疡性结肠炎风险呈显著正相关。
  • 三项队列合并分析显示,规律使用PPI者较非使用者IBD风险升高(HR 1.42;95%CI 1.22-1.65;需伤害人数NNH 3770;95%CI 3668-4369)。
  • 与H2受体拮抗剂直接比较,PPI使用亦与更高IBD风险相关(HR 1.38;95%CI 1.16-1.65)。

关键数值与推荐

  • 规律使用PPI者IBD风险HR 1.42(95%CI 1.22-1.65),NNH 3770(95%CI 3668-4369)。
  • PPI vs H2受体拮抗剂IBD风险HR 1.38(95%CI 1.16-1.65)。

临床怎么用

  • 对需长期规律使用PPI者,尤其有IBD风险因素者,应定期评估用药必要性并考虑替代方案。
  • PPI临床获益显著,不应因该风险信号而擅自停用有明确适应证的PPI。

局限性

  • 绝对风险较低,需结合个体基线风险权衡利弊。
  • 原文摘要未详细列出其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Proton pump inhibitors (PPIs) have a major impact on gut microbiome and immune function, which in turn, may increase the risk of inflammatory bowel disease (IBD). Our aim in this study was to evaluate PPI use and subsequent risk of IBD and subtypes (ie, Crohn's disease and ulcerative colitis). METHODS: This was a pooled analysis of the Nurses' Health Study (NHS, n = 82,869), NHS II (n = 95,141), and UK Biobank (n = 469,397). We included participants with information on personal use of PPIs and free of IBD or cancer at baseline. We evaluated hazard ratios and 95% confidence intervals (CIs) with Cox regression adjusting for lifestyle factors, PPI indications, comorbidities, and other medications. RESULTS: We documented 271 cases of IBD (median follow-up, 12 years) in the pooled NHS cohorts and 1419 cases (median follow-up, 8.1 years) in the UK Biobank. For both pooled NHS cohorts and UK Biobank, regular use of PPIs consistently showed a significantly positive association with IBD, Crohn's disease, and ulcerative colitis risk. Combined analyses of 3 cohorts showed that regular PPI users had an increased risk of IBD as compared with nonusers (hazard ratio, 1.42; 95% CI, 1.22-1.65; number needed to harm, 3770; 95% CI, 3668-4369). Direct comparison with H2 receptor antagonist, a less potent acid suppressor, showed that PPI use was also associated with higher IBD risk (hazard ratio, 1.38; 95% CI, 1.16-1.65). CONCLUSIONS: Regular use of PPIs was associated with an increased risk of IBD and its subtypes. The findings should be interpreted with caution because the absolute risk was low and the clinical benefits of PPIs are substantial.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Xia B, Yang M, Nguyen LH, et al. Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts. Gastroenterology. 2021. PMID: 34389338. doi:10.1053/j.gastro.2021.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。